Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 59%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is actively collaborating and expanding its reach in the biopharmaceutical industry, with partnerships in clinical trials and biomarker development. With promising financials, strong market presence, and strategic developments, the company is poised for long-term growth and success in the field of liquid biopsy and precision oncology. Through their innovative technology and valuable services, Guardant Health is well-positioned to capture a significant share of the growing market for liquid-based cancer tests.

Bears say

Guardant Health is facing several challenges in the future, including unexpected competition in the precision oncology diagnostics market, a crowded market for MRD testing, and the potential for delays in commercializing its upcoming tests. Additionally, the company has a history of burning through large amounts of cash, with a goal of breakeven by 2027. The company may also face balance sheet risks if it decides to raise additional capital in order to make further investments.

GH has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 59% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 22 analysts, GH has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.